Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors to various targeted therapies such as epidermal growth factor receptor inhibitors in lung cancers, and has been prioritized as a key molecular target for cancer therapy. However, the underlying mechanism of resistance to Met-targeting drugs is poorly understood. Here, we describe screening of 1310 genes to search for key regulators related to drug resistance to an anti-Met therapeutic antibody (SAIT301) by using a small interfering RNA-based synthetic lethal screening method. We found that knockdown of 69 genes in Met-amplified MKN45 cells sensitized the antitumor activity of SAIT301. Pathway analysis of these 69 genes implicated fibroblast growth factor receptor (FGFR) as a key regulator for antiproliferative effects of Met-targeting drugs. Inhibition of FGFR3 increased target cell apoptosis through the suppression of Bcl-xL expression, followed by reduced cancer cell growth in the presence of Met-targeting drugs. Treatment of cells with the FGFR inhibitors substantially restored the efficacy of SAIT301 in SAIT301-resistant cells and enhanced the efficacy in SAIT301-sensitive cells. In addition to FGFR3, integrin β3 is another potential target for combination treatment with SAIT301. Suppression of integrin β3 decreased AKT phosphorylation in SAIT301-resistant cells and restored SAIT301 responsiveness in HCC1954 cells, which are resistant to SAIT301. Gene expression analysis using CCLE database shows that cancer cells with high levels of FGFR and integrin β3 are resistant to crizotinib treatment, suggesting that FGFR and integrin β3 could be used as predictive markers for Met-targeted therapy and provide a potential therapeutic option to overcome acquired and innate resistance for the Met-targeting drugs.
INTRODUCTION
Met, a typical receptor tyrosine kinase (RTK) present on cell surfaces, is overexpressed in various tumors and may contribute to the poor prognosis of several malignancies. 1, 2 Met functions to mediate a wide spectrum of signals driven by binding with its ligand hepatocyte growth factor/scatter factor (HGF/SF) and promotes cancer progression, metastasis, cancer cell migration and angiogenesis. 3 HGF/SF binding to Met induces Met dimerization followed by the activation of intracellular signal transduction such as mitogen-activated protein kinase and AKT phosphorylation. 4, 5 Among signal cascades induced by Met activation, AKT phosphorylation is related to cell survival; 6 treatment of cancer cells with an anti-Met antibody results in a marked antiproliferative effect, as well as a concomitant decrease of AKT phosphorylation and an increase of apoptosis. 7 Because of the relevance of Met to cancer biology, it has been a popular target for cancer drug development. 8, 9 Several Met-targeted drugs such as cabozantinib, onartuzumab and tivantinib are in phase 3 registration trials. Every Met-targeted drug being tested in phase 3 clinical trials targets Met and other targets simultaneously or in combination with another drug. 10 Cabozantinib was approved by the United States Food and Drug Administration to treat medullary thyroid cancer; this drug targets Met and vascular endothelial growth factor receptor 2 simultaneously. 11 Onartuzumab, an anti-Met monoclonal human antibody, and tivantinib, a small-molecule Met inhibitor, are in phase 3 clinical trials in patients with non-small-cell lung cancer (NSCLC) in combination with erlotinib. [12] [13] [14] Met has been validated as an oncogenic kinase in preclinical models through the use of selective kinase inhibitors. [15] [16] [17] Although these inhibitors may induce early responses, the emergence of drug resistance is common and limits their effectiveness. 18 The Met pathway was associated with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in EGFR mutant NSCLCs. 19 In turn, the activation of the HER family was shown to be responsible for the resistance of PHA665752, a Met-specific inhibitor, in Met-addicted gastric cancer cells. 20, 21 can occur through MET point mutations, especially at Y1230, 22 MET gene amplification followed by KRAS overexpression in Met-addicted gastric and lung cancer cells, 23 and overexpression of constitutively active SND1-BRAF fusion protein. 24 In NSCLC, the mechanism of acquired resistance to EGFR/Met tyrosine kinase inhibitor was attributed to the activation of mammalian target of rapamycin and the Wnt signaling pathway. 25 However, the underlying mechanism of acquired or inherent resistance to Met-targeted antibodies has not been fully elucidated. [26] [27] [28] Although the relationship between Met and other RTKs in the survival of Met drug-resistant cancer cells remains uncertain, it has been shown that Met inhibitor-driven resistance could be rescued by inactivation of fibroblast growth factor receptor (FGFR) by small molecules. 29, 30 Recently, many approaches have focused on discovering biomarkers for patient selection and exploring novel combination therapies. 31 To identify systematically targets whose inhibition would increase the response of cancer cells to Met inhibitors, we performed medium-throughput small interfering RNA (siRNA) library synthetic lethal screening targeting genes associated with systems biology-derived EGFR and Met signaling pathways. 32 Here, we show that FGFR could have a role as an alternative driver kinase for Met because dependence on either FGFR or Met can be compensated by activation of the other kinase. Therefore, simultaneous inhibition of FGFR and Met or intervention at a common downstream effector such as AKT is required for effective Met-targeted anticancer therapeutics.
Previous studies have shown that integrin β1 mediates EGFR drug resistance and its association with the Met signaling pathway in NSCLCs. 33 Integrin β subunits are adhesion molecules involved in cell survival and cancer resistance to chemotherapy in breast cancers. 34, 35 Here, we identify significant cross-talk between integrin β3 and Met in HCC1954 breast cancer cells and investigate the mechanism of Met drug resistance related to integrin signaling. We also demonstrate that perturbation of integrin β3 and FGFR signaling significantly inhibits proliferation of SAIT301-resistant MKN45 cells. These data provide a strong rationale for the use of integrin β3 and FGFR inhibitors in Met-amplified tumors that have become resistant to selective Met inhibition, or to combined therapy to prevent these resistance mechanisms. Our findings demonstrate a specific cross-talk of integrin, FGFR and Met pathways and suggest the partial overlap of downstream signaling and common cellular effects of each pathway.
RESULTS
Synthetic lethal screening to identify sensitizers of cellular response to a Met inhibitor To identify molecular determinants that modulate cellular responses to Met-targeted therapies, we developed an siRNA library and performed synthetic lethal screening using a Met-specific monoclonal antibody, SAIT301. 7, 36 Previously, we reported that SAIT301 promotes Met degradation via an LRIG1-mediated pathway. SAIT301 treatment promoted the binding of Met with LRIG1, bypassing the Cbl-mediated Met degradation pathway that requires Met activation. This unique mechanism permits SAIT301 to induce Met degradation without triggering Met signaling activation, and consequently activate cellular apoptosis. 7 The siRNA library used in our studies comprised of siRNAs targeting 1310 genes. We used Met as a seed node to collect data from public archives reporting curated pathway information, protein-protein interactions, association in protein complexes and putative genes responsive to Met antibodies (Supplementary Figure S1) . The data mining provided 828 genes in the Met-centered network. As there is good evidence of cross-talk among the Met and EGFR pathways, we included the 638 genes from an EGFR-centered network described by one of us (LMW). 32 A total of 1310 genes comprised the final network, which included 156 genes shared by the two networks (Supplementary Figure S1) .
The MKN45 gastric cancer cell line is dependent on Met signaling for proliferation and survival. This cell line was screened with the siRNA library targeting 1310 genes in combination with vehicle or SAIT301 at IC 20 (inhibitory concentration 20). Primary hits were identified as genes that, when knocked down, cause reduction of cell viability by >15% of normalized cell viability in the presence of SAIT301 compared with vehicle control (false discovery rate (FDR) o 20% and sensitization index (SI) o0.85) in three independent experiments.
To further validate the positive hits, MKN45 cells were screened using the deconvoluted siRNAs that target candidate genes identified in the initial screening studies. Statistical analysis confirmed that 69 validated genes significantly increased the sensitivity of MKN45 cells to SAIT301 treatment (Table 1) . Therefore, the 69 genes were considered to be potential mediators of resistance to SAIT301. Figure 1a demonstrates that the distribution of viability and SI of 69 hits was independent of the viability reduction induced by siRNA knockdown in the absence of antibody treatment. Most of the sensitizing hits were connected in a physically interacting network (Figure 1b) , and the distribution of these hits was random in the context of the full library.
We next assessed the efficacy of these 69 putative sensitizers to SAIT301 treatment in seven other cell lines: NCI-N87 (gastric cancer), HCC827 (lung cancer), BxPC-3 (pancreatic cancer), H1993 (lung cancer), A549 (lung cancer), RKO (colon cancer) and HCC1954 (breast cancer). As shown in Figure 1c , 24 genes sensitized at least three of these cell lines to the effects of a Met-targeting antibody.
Pathway analysis of the targets from the screen implicates the FGFR and integrin pathways as key regulators of the efficacy of a Met-targeting antibody To delineate the functional associations and identify potential interacting partners of the 69 validated hits, we evaluated the hit network using the Ingenuity Pathway Analysis (IPA) software (http://www.ingenuity.com/). Gene set enrichment analysis showed that seven canonical signaling pathways were used by the identified 69 hits (Po0.015). The genes involved in each individual pathway are summarized in Figure 2a . As these pathways were all statistically significantly enriched by the analysis, we examined the frequency of the genes shared by different pathways. Genes such as RAF1, AKT2, SOS1 and KRAS (shaded in blue) are heavily shared by six out of seven pathways, indicating that the RAS/RAF/MEK and PI3K/AKT signaling pathways are common downstream pathways. ITGB3, FGFR3 and SGK1 (red, orange shades) are not shared by more than two signaling pathways; therefore, representing the involvement of individual signaling pathways. Subsequent network analysis corroborated several interacting partners of Met signaling that potentially mediate resistance to Met inhibitors. Among them, highly ranked partners are cell surface receptors triggering intracellular signaling system, such as FGFR3, involved in the FGFR signaling pathway, and ITGB3, triggering the integrin signaling pathway. Depletion of these two genes significantly reduces cancer cell viability when used in combination with SAIT301 treatment. IPA analysis of the distribution of connections indicates potential interactions among the FGFR, integrin and Met signaling pathways (Figure 2b ), which may serve as compensatory pathways for escape from Met blockade.
On the basis of these findings, FGFR3 and ITGB3 were selected for further studies that explore the potential for SAIT301-based combination therapy. and vemurafenib in melanoma. 37 In the synthetic lethal screening studies described here, the growth inhibitory effect of SAIT301 was increased with concomitant knockdown of the FGFR3 gene in MKN45 cells compared with control siRNA-transfected MKN45 cells (Figure 3a) . Knockdown of FGFR3 gene also increased the growth inhibitory effect of other Met inhibitors such as PHA665752 and XL-184 ( Figures 3b and c) ; PHA665752 is a small-molecule inhibitor that specifically targets Met, 17 and XL-184 is a small-molecule inhibitor that targets the Met, vascular endothelial growth factor receptor 2 and Ret kinases. 38 We then investigated the mechanisms through which FGFR3 knockdown promotes the antitumor activity of SAIT301 in MKN45 cells. FGFR3 knockdown increased the apoptosis of MKN45 cells compared with treatment with SAIT301 alone (Figure 3d ). Apoptosis induction by FGFR3 suppression was further confirmed by cleavage of poly ADP ribose polymerase (PARP) and caspase-3 (Supplementary Figure S2) . It is reported that FGFR3 inhibition leads to apoptosis due to decreased expression of Bcl-2. 39 We therefore examined the expression of Bcl-xL, which is transcribed by BCL2L1, one of the 69 sensitizers identified by our synthetic lethal screening. FGFR3 knockdown substantially enhanced reduction of Bcl-xL protein and SAIT301-induced PARP cleavage ( Figure 3e ). To determine the underlying signaling mechanism for the regulation of Bcl-xL expression, we tested the mitogen-activated protein kinase inhibitors (SB203580 and U0126) and an AKT inhibitor (MK-2206). Interestingly, a p38 inhibitor, SB203580, in the presence of a Met-targeting antibody, suppressed Bcl-xL expression, followed by induction of apoptosis (Figure 3f ). Consistent with this finding, BCL2L1 knockdown also increased the growth inhibitory effect of SAIT301 (Figure 3g ). In addition, FGFR signaling activation by basic fibroblast growth factor treatment restored the growth inhibition induced by SAIT301 (Supplementary Figure S3) , further confirming the role of FGFR activity in cellular sensitivity to a Met-targeting antibody. These data strongly support that FGFR signaling has an antiapoptotic role in MKN45 cells by sustaining Bcl-xL expression, and FGFR suppression makes these cells susceptible to apoptosis induced by Met-targeting drugs.
Combinations of selective FGFR inhibitors and Met inhibitors synergistically inhibit cancer cell growth accompanied by induction of apoptosis Because genetic knockdown of FGFR3 sensitizes MKN45 cells to SAIT301 treatment, we assessed whether pharmacological inhibitors of the FGFR family have similar effects. The smallmolecule tyrosine kinase inhibitor, PD173074, is a specific and potent inhibitor of the FGFR family. 40 PD173074 potently inhibited tyrosine phosphorylation of FGFR in MKN45 cells and siRNAs directed against other FGFR family members also increased Mettargeted antibody-mediated efficacy (Supplementary Figure S4) . MKN45 cell viability was reduced by Met inhibition using SAIT301 alone, and this inhibition was significantly enhanced by the addition of PD173074 (combination index (CI) o1; isobologram analysis; Figure 4a ). PD173074 treatment also promoted the cell growth inhibitory effect of crizotinib, a small-molecule targeting Met, as well as ALK, 16 PHA665752 and XL-184 (Figures 4b-d) . To further confirm this effect, we tested EBC1, a lung cancer cell line that is known to be addicted to Met signaling for its survival. 7 Cell growth inhibitory effect of SAIT301 was increased by the addition of PD173074 in EBC1 cells (CI o 1; isobologram analysis; Figure 4e ). Like MKN45 cells, EBC1 cells showed marked reduction of cell viability when treated with Met-targeting inhibitors, PHA665752 and XL-184, in the presence of PD173074 compared with the treatment with either drug alone (Supplementary Figures  S5a and b) . We tested another selective FGFR inhibitor, NVP-BGJ398 (hereinafter referred to as BGJ398), that is currently in phase I clinical trials. 41 BGJ398 combined with SAIT301 also has a synergistic effect on growth inhibition of both EBC1 and MKN45 cells (CI o 1; isobologram analysis; Supplementary Figure S6) . We then determined whether the effects of combining FGFR inhibitors with SAIT301 were because of induction of apoptosis. SAIT301-mediated cell apoptosis in EBC1 cells was markedly enhanced with the addition of PD173074 or BGJ398 (Figure 4f) . Furthermore, as measured by immunoblot analysis, PD173074 significantly induced PARP cleavage when combined with SAIT301 (Figure 4g ). PD173074 alone had no effect on the protein levels of Bcl-xL, but exposure to the combination of PD173074 and SAIT301 induced a nearly complete ablation of Bcl-xL. As BCL2L1 knockdown improved SAIT301 efficacy in MKN45 cells, combined treatment with SAIT301 and ABT-263, a potent inhibitor of Figure 2 . Canonical pathway enrichment and network analysis of 69 validated hits reveal links between Met and FGFR, integrin signaling pathway. (a) In silico analysis was performed using the IPA software and categorized the hits according to their proposed enrichment for canonical pathways. The top seven signaling pathways are plotted based on the number of genes identified within each pathway (P o0.015). Hits were included in one signaling pathway (red shades); two signaling pathways (orange shades); three signaling pathways (yellow shades); four signaling pathways (green shades); and six signaling pathways (blue shades). (b) Interactions among hits and potential interaction partners were accessed using IPA. Nodes represent genes, with their shape representing the functional class of the gene product, and the edges indicate the biological relationship between the nodes. Hits are represented in pink outlined symbols, and interaction partners not in the hit list are in black.
Bcl-xL, 42 synergistically inhibited cell growth of EBC1 cells (Figure 4h ). Crizotinib also synergized with BGJ398 in EBC1 cells (Figures 4i and j) . BGJ398 treatment increased the apoptotic rate induced by Met inhibitors, PHA665752 or XL-184 (Figures 4k  and l) . These data suggest that FGFR activation maintains antiapoptotic regulation in Met-addicted cancer cells. We further confirmed the combination effect using a nude mouse heterotropic MKN45 xenograft model. SAIT301 demonstrated an inhibition of tumor growth, resulting in the reduction of tumor volume by 27.8%. Combination treatment of SAIT301 and BGJ398 resulted in the reduction of tumor volume by 41.2% (Supplementary Figure S7) . These findings further support the concept that FGFR inhibitors and Met-targeted drugs cooperatively inhibit cancer cell growth.
MKN45-SAIT301-resistant cells display activation of FGFR3, which confers resistance to Met inhibition through reactivation of AKT signaling As acquired resistance is a general phenomenon in targeted therapy, identifying the relevant resistance mechanisms can improve the clinical benefit of targeted cancer drugs. 43 We created SAIT301-resistant clones of MKN45 cells and EBC1 cells that originally were sensitive to this antibody. 7 The viability of SAIT301-resistant clone nos. 1 and 24 was not affected by SAIT301 treatment at up to 2 μg/ml concentrations that induced~50% growth inhibition in parental MKN45 cells (Figure 5a ). To characterize underlying molecular mechanisms of resistance in these SAIT301-resistant clones, we investigated the activation status of several signaling mediators. As shown in Figure 5b , the phosphorylation of FGFR3 and AKT is higher in SAIT301-resistant clones compared with the parental MKN45 cells. To test if insensitivity of resistant cells to SAIT301 is due to the activation of AKT, we performed cell viability assays with SAIT301 in the presence of an AKT inhibitor, MK-2206. 44, 45 AKT inhibition using MK-2206 resensitized MKN45-SAIT301-resistant cells to SAIT301 in a dose-dependent manner (Figure 5c and Supplementary Figure S8a) .
Because AKT is commonly involved in the signaling of several RTKs, FGFR could be an upstream RTK of activated AKT in SAIT301-resistant clones. As shown in Figure 5d , SAIT301-mediated inhibition of AKT phosphorylation was significantly enhanced by cotreatment with PD173074. To investigate the role of FGFR in acquired resistance for SAIT301, MKN45-SAIT301-resistant clone no. 24 cells were treated with SAIT301 and BGJ398. Concomitant inhibition of Met and FGFR signaling using SAIT301 and BGJ398 The apoptotic rate of EBC1 cells was determined by caspase activation using Caspase 3/7 Glo assay after treating with 0.08 μg/ml of SAIT301 alone or in combination with the FGFR inhibitors (PD173074, 10 μM; BGJ398, 5 μM) for 72 h. Cell numbers were normalized in parallel wells using CTG assay. The relative caspase-3/7 activity (%) is represented as a percentage comparison with the control group (no antibody treatment). (g) Cleaved PARP and Bcl-xL were detected by immunoblotting assay with EBC1 cells treated with 0.4 μg/ml of SAIT301 alone or in combination with PD173074 (10 μM) for 72 h. (h) The viability of EBC1 cells was measured by CTG assay after treating with 0.08 μg/ml of SAIT301 alone or in combination with the Bcl-xL inhibitor (ABT-263, 0.5 μM) for 72 h. The relative cell viability (%) represents the percent growth as compared with the control group (no antibody and inhibitor treatment). (i) The viability of EBC1 cells was measured by CTG assay after treating with 10 nM of crizotinib alone or in combination with the FGFR inhibitor (BGJ398, 5 μM) for 72 h. The relative cell viability (%) represents the percent growth as compared with the control group (no inhibitor treatment). (j) The apoptotic rate of EBC1 cells was determined by caspase activation using Caspase 3/7 Glo assay after treating with 20 nM of crizotinib alone or in combination with the FGFR inhibitor (BGJ398, 5 μM) for 72 h. Cell numbers were normalized in parallel wells using CTG assay. The relative caspase-3/7 activity (%) is represented as a percentage comparison with the control group (no antibody treatment). (k) The apoptotic rate of EBC1 cells was determined by caspase activation using Caspase 3/7 Glo assay after treating with 20 nM of PHA665752 alone or in combination with the FGFR inhibitor (BGJ398, 5 μM) for 72 h. Cell numbers were normalized in parallel wells using CTG assay. The relative caspase-3/7 activity (%) is represented as a percentage comparison with the control group (no antibody treatment). (l) The apoptotic rate of EBC1 cells was determined by caspase activation using Caspase 3/7 Glo assay after treating with 1 μM of XL-184 alone or in combination with the FGFR inhibitor (BGJ398, 5 μM) for 72 h. Cell numbers were normalized in parallel wells using CTG assay. The relative caspase-3/7 activity (%) is represented as a percentage comparison with the control group (no antibody treatment). Figure S8b) . To confirm the role of FGFR function in acquired resistance to Met-targeting therapy, we tested EBC1-SAIT301-resistant clones, and found that AKT phosphorylation was elevated in these cells (Supplementary Figure S9a) . Combined inhibition of Met and FGFR led to a reduction of cell viability in a dose-dependent manner (Figure 5f and Supplementary Figure S9b . These data further support FGFR and its downstream pathway-mediated signaling as a potentially important mechanism of acquired resistance to Met inhibition.
ITGB3 inhibition improves the antitumor efficacy of SAIT301 in cancer cells with acquired and innate resistance to Met inhibition ITGB3 is another highly ranked hit from our synthetic lethal screening study, and ITGB3 is known to influence the development and progression of breast cancers. 46, 47 To investigate the relationship of ITGB3 expression to Met resistance, knockdown assays were conducted with MKN45-SAIT301-resistant cells. As shown in Figure 6a , ITGB3 suppression by siRNA enhanced the effects of SAIT301 on cell viability. A potent integrin β3 inhibitor, cilengitide, 19, 48 also enhanced the effects of SAIT301 in MKN45-SAIT301-resistant cells (Figure 6b ). Combination treatment of cilengitide further enhanced SAIT301-mediated inhibition of AKT phosphorylation compared with treatment with SAIT301 alone (Figure 6c ).
HCC1954 breast cancer cells have high Met protein expression, and were used to test the efficacy of Met-targeting drugs.
49
HCC1954 cells did not respond to SAIT301 treatment and were shown to have very low protein levels of FGFR3 but relatively high levels of integrin β3 (data not shown). It is worth noting that an FGFR inhibitor, PD173074, yields no synergistic inhibition of proliferation with SAIT301 in these cells (data not shown). The reason might be low levels of FGFR3 phosphorylation compared with MKN45 cells in which FGFR inhibitors have synergistic effects with SAIT301 (Supplementary Figure S10) . To investigate the role of ITGB3 in innate resistance to SAIT301, the effect of knockdown of ITGB3 was tested in HCC1954 cells. The combination of SAIT301 treatment and ITGB3 knockdown resulted in greater inhibition of cell growth (Figure 6d ) and AKT phosphorylation (Figure 6e ) as compared with SAIT301 treatment alone.
In addition, to elucidate the potential implication of FGFR and ITGB3 in cancer cell responses to Met-targeting therapy in general, we first analyzed IC 50 (half-maximal inhibitory concentration) values for 504 cell lines following treatment with crizotinib (PF-2341066) from the CCLE database (http://www.broadinstitute. org/ccle/) and categorized each cell line into three tiers (low, medium and high) based on the expression levels of FGFR2, FGFR3 and ITGB3, with cutoffs at 33 and 67 percentile values. Cell lines that have 'low' expression for all three genes were assigned to Group A, whereas Group B consisted of cell lines that have 'high' expression for at least one of the three genes. The median IC 50 values for Groups A and B are 6.81 and 8.00, respectively (P = 0.045 by Mann-Whitney U-test) (Figure 6f ). These data provide molecular validation of ITGB3 or FGFR family as being synthetically lethal with a Met inhibitor under defined conditions.
DISCUSSION
As it is well known that repeated treatment with targeted cancer drugs eventually leads to drug resistance, 18 investigating the mechanism of acquired resistance is important in the development of cancer drugs. siRNA screening has been demonstrated as an effective method for identifying the potential mechanisms of acquired or inherent resistance to certain drugs. 50, 51 We developed an siRNA library centered to Met and EGFR signaling and performed synthetic lethal screening to search for key regulators related to drug resistance against an anti-Met therapeutic antibody. The siRNA library used in our studies was comprised of siRNAs targeting the 1310 Met-and EGFR-centered genes. By focusing on the statistically significant viability changes and by filtering off-target effects by requiring two or more siRNAs to replicate the effects, we were able to identify 69 genes connected to several signaling pathways that likely mediate SAIT301 resistance. By examining the frequency of the genes shared by these seven putative signaling pathways, we found many heavily shared hits (RAF1, AKT2, SOS1 and KRAS), located at the mediator level of cross-talk involved in resistance, did not represent any specific pathway. In contrast, canonical pathway enrichment and network analysis of the 69 gene validated hit set revealed enrichment of the integrin and FGFR signaling pathways. ITGB3 and FGFR3 regulate the integrin and FGF signaling pathways, respectively, are well-enriched surface molecules and are easily accessible to targeted therapies. Furthermore, potential interaction indicated compensatory pathways among the FGFR, integrin and Met signaling pathways.
Recent reports have referred to signaling cross-talk between FGFR and Met. In acute myeloid leukemia, FGFR1 is responsible for innate resistance to crizotinib by inducing HGF transcription. 29 In turn, HGF secretion compensates for cancer cell growth inhibition by BGJ398, a selective FGFR inhibitor. 52 The results from the present study support previous findings, as we show that suppression of FGFR can significantly improve the antiproliferative effects of Met-targeting drugs in Met-addicted cell lines such as MKN45 (gastric cancer) and EBC1 (lung cancer). In MKN45, FGFR signaling has an antiapoptotic function by retaining Bcl-xL expression through constitutively active p38, and suppresses the transcription of proapoptotic genes such as TRAIL and BIM (data not shown). Pharmacological inhibitors targeting FGFR synergize with Met-targeting drugs in preventing cancer cell growth in vitro and in vivo. These data suggest that a Met-targeting drug in combination with an FGFR inhibitor warrants further interrogation in combination therapy.
In the present study, we demonstrated that SAIT301-resistant clones obtained through prolonged treatment with SAIT301 exhibit enhanced FGFR3 activation and increased AKT phosphorylation. AKT activation appears to be a key mechanism for resistance to the Met-targeting antibody, and MK-2206, an AKT inhibitor, restores the sensitivity of resistant cells to SAIT301 (Figure 5c and Supplementary Figure S8a) . FGFR signaling compensates for the inhibition of Met in two ways: by retaining antiapoptotic molecules and by activating PI3K/AKT signaling. These data provide the rationale for further investigation combinations of Met and FGFR inhibitors to overcome acquired resistance.
We also examined integrin signaling, which emerged as another highly ranked resistance-promoting signaling pathway in the analysis of our screening studies. Met binds to integrin β3 and promotes the migration and invasion of mammary epithelial cells. 47 Suppression of ITGB3 improved the efficacy of SAIT301 in vitro, through antiproliferative effects but not by facilitating apoptosis in MKN45 cells (data not shown). Cilengitide, an integrin β3 inhibitor, also restored sensitivity to SAIT301 in SAIT301-resistant MKN45 cells. In addition, integrin signaling may be related to innate resistance to SAIT301. SAIT301 alone has no antiproliferative effect on HCC1954, even though this cell line possesses a relatively high level of Met expression compared with other breast cancer cell lines. However, ITGB3 inhibition combined with SAIT301 had significant antitumor effects. Interestingly, transcript levels of ITGB3 are high in HCC1954 compared with other Met-addicted cell lines, such as MKN45 and EBC1 (data not shown). These findings imply that ITGB3 can be used as a putative predictive marker as well as a target for combination therapy using SAIT301. Although future studies will be required to confirm the hypothesis that the expression of FGFR and ITGB3 can both predict the efficacy of SAIT301 and comprise a new combination treatment strategy, our synthetic lethal screening approach appears to be a useful way to identify potential candidates for combination with a tumor-targeting monoclonal antibody that perturbs cancer cell signaling.
In summary, we have identified a number of key regulators of resistance to a Met-targeting antibody by synthetic lethal screening. Among them, we have validated that FGFR and integrin are important components for resistance mechanism toward SAIT301, and possibly for Met inhibitors in general. Combining Met inhibitors with FGFR or integrin inhibitors may be useful to mitigate the development of clinical resistance. In addition, both FGFR and integrin may be useful as predictive markers for clinical response to Met inhibitors.
MATERIALS AND METHODS siRNA library construction
We have previously reported on an EGFR network-targeted library, 32 using EGFR as the seed protein. This network was involved in this study based on the evidence of cross-talk among the Met and EGFR pathways. A distinct Met-centered network containing 828 genes was developed using the open-source software tool, Cytoscape (www.cytoscape.org), with Met as the seed protein. Bioinformatic databases were mined for protein-protein interactions, protein complexes, members of canonical pathways linked with Met and additional genes include genes encoding RTKs and differentially expressed genes in SAIT301-treated NCI-H441 cells. These sources included BIND, BioGRID, DIP, HPRD, IntAct, MiMI, MINT, STRING, Biocarta, Linnea, Protein Lounge, STKE and literature searches ( Figure S1 ). This resulted in an siRNA library comprising siRNAs targeting 1310 genes.
Further testing of identified sensitizing genes in responsive and non-responsive cell lines
We further tested the 69 validated hits for sensitization to SAIT301 in three SAIT301-responsive cell lines (BxPC-3, HCC827 and H1993) versus four SAIT301-non-responsive cell lines (A549, NCI-N87, RKO and HCC1954). Cells were transfected with siRNA pools comprising two most effective siRNAs identified during the validation. SI and statistical significance were calculated as in the Supplementary Information. All experiments were performed at least three times independently.
Network analysis with 69 validated hits
For canonical pathway enrichment, network analysis and gene interaction networks were generated using IPA (Ingenuity Systems, Redwood City, CA, USA; http: \\www.Ingenuity.com). Sixty-nine validated hits were uploaded into the application. MiMI plugin for Cytoscape was used to access the integrated molecular data and to retrieve interaction map that display protein interactions. All 69 genes were hierarchically clustered as distance measure with Cluster 3.0, and then visualized using Java TreeView (version1.1.6r2, Jtreeview.sourceforge.net).
Generation of SAIT301-resistant MKN45 and EBC1 cells in vitro
To generate SAIT301-resistant clones, MKN45 and EBC1 cells were exposed to increasing concentrations (range 1-10 μg/ml) of SAIT301 over 3 months in vitro. To confirm that these clones are durably resistant to SAIT301, cell viability tests were performed after the resistant clones had been cultured in the presence or absence of SAIT301 for 6 weeks.
Cell viability and apoptosis assay
Cell viability test and apoptosis assay were performed as reported previously. 7, 36 Synergism for drug combination was quantified by the CI, where CIo 1 and CI = 0 indicate synergistic and additive effects, respectively. CI was calculated with the CalcuSyn software (Biosoft, Cambridge, UK).
